Cargando…

Future perspectives in melanoma research: Meeting report from the “Melanoma Bridge”. Napoli, December 1st–4th 2015

The sixth “Melanoma Bridge Meeting” took place in Naples, Italy, December 1st–4th, 2015. The four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news in immunotherapy; and 4) tumor microenvironment and biomarkers. Recent advances in tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A., Agarwala, Sanjiv, Botti, Gerardo, Cesano, Alessandra, Ciliberto, Gennaro, Davies, Michael A., Demaria, Sandra, Dummer, Reinhard, Eggermont, Alexander M., Ferrone, Soldano, Fu, Yang Xin, Gajewski, Thomas F., Garbe, Claus, Huber, Veronica, Khleif, Samir, Krauthammer, Michael, Lo, Roger S., Masucci, Giuseppe, Palmieri, Giuseppe, Postow, Michael, Puzanov, Igor, Silk, Ann, Spranger, Stefani, Stroncek, David F., Tarhini, Ahmad, Taube, Janis M., Testori, Alessandro, Wang, Ena, Wargo, Jennifer A., Yee, Cassian, Zarour, Hassane, Zitvogel, Laurence, Fox, Bernard A., Mozzillo, Nicola, Marincola, Francesco M., Thurin, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111349/
https://www.ncbi.nlm.nih.gov/pubmed/27846884
http://dx.doi.org/10.1186/s12967-016-1070-y
_version_ 1782467854664204288
author Ascierto, Paolo A.
Agarwala, Sanjiv
Botti, Gerardo
Cesano, Alessandra
Ciliberto, Gennaro
Davies, Michael A.
Demaria, Sandra
Dummer, Reinhard
Eggermont, Alexander M.
Ferrone, Soldano
Fu, Yang Xin
Gajewski, Thomas F.
Garbe, Claus
Huber, Veronica
Khleif, Samir
Krauthammer, Michael
Lo, Roger S.
Masucci, Giuseppe
Palmieri, Giuseppe
Postow, Michael
Puzanov, Igor
Silk, Ann
Spranger, Stefani
Stroncek, David F.
Tarhini, Ahmad
Taube, Janis M.
Testori, Alessandro
Wang, Ena
Wargo, Jennifer A.
Yee, Cassian
Zarour, Hassane
Zitvogel, Laurence
Fox, Bernard A.
Mozzillo, Nicola
Marincola, Francesco M.
Thurin, Magdalena
author_facet Ascierto, Paolo A.
Agarwala, Sanjiv
Botti, Gerardo
Cesano, Alessandra
Ciliberto, Gennaro
Davies, Michael A.
Demaria, Sandra
Dummer, Reinhard
Eggermont, Alexander M.
Ferrone, Soldano
Fu, Yang Xin
Gajewski, Thomas F.
Garbe, Claus
Huber, Veronica
Khleif, Samir
Krauthammer, Michael
Lo, Roger S.
Masucci, Giuseppe
Palmieri, Giuseppe
Postow, Michael
Puzanov, Igor
Silk, Ann
Spranger, Stefani
Stroncek, David F.
Tarhini, Ahmad
Taube, Janis M.
Testori, Alessandro
Wang, Ena
Wargo, Jennifer A.
Yee, Cassian
Zarour, Hassane
Zitvogel, Laurence
Fox, Bernard A.
Mozzillo, Nicola
Marincola, Francesco M.
Thurin, Magdalena
author_sort Ascierto, Paolo A.
collection PubMed
description The sixth “Melanoma Bridge Meeting” took place in Naples, Italy, December 1st–4th, 2015. The four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news in immunotherapy; and 4) tumor microenvironment and biomarkers. Recent advances in tumor biology and immunology has led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS) of cancer patients. Immunotherapies in particular have emerged as highly successful approaches to treat patients with cancer including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin’s disease. Specifically, many clinical successes have been using checkpoint receptor blockade, including T cell inhibitory receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death-1 (PD-1) and its ligand PD-L1. Despite demonstrated successes, responses to immunotherapy interventions occur only in a minority of patients. Attempts are being made to improve responses to immunotherapy by developing biomarkers. Optimizing biomarkers for immunotherapy could help properly select patients for treatment and help to monitor response, progression and resistance that are critical challenges for the immuno-oncology (IO) field. Importantly, biomarkers could help to design rational combination therapies. In addition, biomarkers may help to define mechanism of action of different agents, dose selection and to sequence drug combinations. However, biomarkers and assays development to guide cancer immunotherapy is highly challenging for several reasons: (i) multiplicity of immunotherapy agents with different mechanisms of action including immunotherapies that target activating and inhibitory T cell receptors (e.g., CTLA-4, PD-1, etc.); adoptive T cell therapies that include tissue infiltrating lymphocytes (TILs), chimeric antigen receptors (CARs), and T cell receptor (TCR) modified T cells; (ii) tumor heterogeneity including changes in antigenic profiles over time and location in individual patient; and (iii) a variety of immune-suppressive mechanisms in the tumor microenvironment (TME) including T regulatory cells (Treg), myeloid derived suppressor cells (MDSC) and immunosuppressive cytokines. In addition, complex interaction of tumor-immune system further increases the level of difficulties in the process of biomarkers development and their validation for clinical use. Recent clinical trial results have highlighted the potential for combination therapies that include immunomodulating agents such as anti-PD-1 and anti-CTLA-4. Agents targeting other immune inhibitory (e.g., Tim-3) or immune stimulating (e.g., CD137) receptors on T cells and other approaches such as adoptive cell transfer are tested for clinical efficacy in melanoma as well. These agents are also being tested in combination with targeted therapies to improve upon shorter-term responses thus far seen with targeted therapy. Various locoregional interventions that demonstrate promising results in treatment of advanced melanoma are also integrated with immunotherapy agents and the combinations with cytotoxic chemotherapy and inhibitors of angiogenesis are changing the evolving landscape of therapeutic options and are being evaluated to prevent or delay resistance and to further improve survival rates for melanoma patients’ population. This meeting’s specific focus was on advances in immunotherapy and combination therapy for melanoma. The importance of understanding of melanoma genomic background for development of novel therapies and biomarkers for clinical application to predict the treatment response was an integral part of the meeting. The overall emphasis on biomarkers supports novel concepts toward integrating biomarkers into personalized-medicine approach for treatment of patients with melanoma across the entire spectrum of disease stage. Translation of the knowledge gained from the biology of tumor microenvironment across different tumors represents a bridge to impact on prognosis and response to therapy in melanoma. We also discussed the requirements for pre-analytical and analytical as well as clinical validation process as applied to biomarkers for cancer immunotherapy. The concept of the fit-for-purpose marker validation has been introduced to address the challenges and strategies for analytical and clinical validation design for specific assays.
format Online
Article
Text
id pubmed-5111349
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51113492016-11-25 Future perspectives in melanoma research: Meeting report from the “Melanoma Bridge”. Napoli, December 1st–4th 2015 Ascierto, Paolo A. Agarwala, Sanjiv Botti, Gerardo Cesano, Alessandra Ciliberto, Gennaro Davies, Michael A. Demaria, Sandra Dummer, Reinhard Eggermont, Alexander M. Ferrone, Soldano Fu, Yang Xin Gajewski, Thomas F. Garbe, Claus Huber, Veronica Khleif, Samir Krauthammer, Michael Lo, Roger S. Masucci, Giuseppe Palmieri, Giuseppe Postow, Michael Puzanov, Igor Silk, Ann Spranger, Stefani Stroncek, David F. Tarhini, Ahmad Taube, Janis M. Testori, Alessandro Wang, Ena Wargo, Jennifer A. Yee, Cassian Zarour, Hassane Zitvogel, Laurence Fox, Bernard A. Mozzillo, Nicola Marincola, Francesco M. Thurin, Magdalena J Transl Med Meeting Report The sixth “Melanoma Bridge Meeting” took place in Naples, Italy, December 1st–4th, 2015. The four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news in immunotherapy; and 4) tumor microenvironment and biomarkers. Recent advances in tumor biology and immunology has led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS) of cancer patients. Immunotherapies in particular have emerged as highly successful approaches to treat patients with cancer including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin’s disease. Specifically, many clinical successes have been using checkpoint receptor blockade, including T cell inhibitory receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death-1 (PD-1) and its ligand PD-L1. Despite demonstrated successes, responses to immunotherapy interventions occur only in a minority of patients. Attempts are being made to improve responses to immunotherapy by developing biomarkers. Optimizing biomarkers for immunotherapy could help properly select patients for treatment and help to monitor response, progression and resistance that are critical challenges for the immuno-oncology (IO) field. Importantly, biomarkers could help to design rational combination therapies. In addition, biomarkers may help to define mechanism of action of different agents, dose selection and to sequence drug combinations. However, biomarkers and assays development to guide cancer immunotherapy is highly challenging for several reasons: (i) multiplicity of immunotherapy agents with different mechanisms of action including immunotherapies that target activating and inhibitory T cell receptors (e.g., CTLA-4, PD-1, etc.); adoptive T cell therapies that include tissue infiltrating lymphocytes (TILs), chimeric antigen receptors (CARs), and T cell receptor (TCR) modified T cells; (ii) tumor heterogeneity including changes in antigenic profiles over time and location in individual patient; and (iii) a variety of immune-suppressive mechanisms in the tumor microenvironment (TME) including T regulatory cells (Treg), myeloid derived suppressor cells (MDSC) and immunosuppressive cytokines. In addition, complex interaction of tumor-immune system further increases the level of difficulties in the process of biomarkers development and their validation for clinical use. Recent clinical trial results have highlighted the potential for combination therapies that include immunomodulating agents such as anti-PD-1 and anti-CTLA-4. Agents targeting other immune inhibitory (e.g., Tim-3) or immune stimulating (e.g., CD137) receptors on T cells and other approaches such as adoptive cell transfer are tested for clinical efficacy in melanoma as well. These agents are also being tested in combination with targeted therapies to improve upon shorter-term responses thus far seen with targeted therapy. Various locoregional interventions that demonstrate promising results in treatment of advanced melanoma are also integrated with immunotherapy agents and the combinations with cytotoxic chemotherapy and inhibitors of angiogenesis are changing the evolving landscape of therapeutic options and are being evaluated to prevent or delay resistance and to further improve survival rates for melanoma patients’ population. This meeting’s specific focus was on advances in immunotherapy and combination therapy for melanoma. The importance of understanding of melanoma genomic background for development of novel therapies and biomarkers for clinical application to predict the treatment response was an integral part of the meeting. The overall emphasis on biomarkers supports novel concepts toward integrating biomarkers into personalized-medicine approach for treatment of patients with melanoma across the entire spectrum of disease stage. Translation of the knowledge gained from the biology of tumor microenvironment across different tumors represents a bridge to impact on prognosis and response to therapy in melanoma. We also discussed the requirements for pre-analytical and analytical as well as clinical validation process as applied to biomarkers for cancer immunotherapy. The concept of the fit-for-purpose marker validation has been introduced to address the challenges and strategies for analytical and clinical validation design for specific assays. BioMed Central 2016-11-15 /pmc/articles/PMC5111349/ /pubmed/27846884 http://dx.doi.org/10.1186/s12967-016-1070-y Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Meeting Report
Ascierto, Paolo A.
Agarwala, Sanjiv
Botti, Gerardo
Cesano, Alessandra
Ciliberto, Gennaro
Davies, Michael A.
Demaria, Sandra
Dummer, Reinhard
Eggermont, Alexander M.
Ferrone, Soldano
Fu, Yang Xin
Gajewski, Thomas F.
Garbe, Claus
Huber, Veronica
Khleif, Samir
Krauthammer, Michael
Lo, Roger S.
Masucci, Giuseppe
Palmieri, Giuseppe
Postow, Michael
Puzanov, Igor
Silk, Ann
Spranger, Stefani
Stroncek, David F.
Tarhini, Ahmad
Taube, Janis M.
Testori, Alessandro
Wang, Ena
Wargo, Jennifer A.
Yee, Cassian
Zarour, Hassane
Zitvogel, Laurence
Fox, Bernard A.
Mozzillo, Nicola
Marincola, Francesco M.
Thurin, Magdalena
Future perspectives in melanoma research: Meeting report from the “Melanoma Bridge”. Napoli, December 1st–4th 2015
title Future perspectives in melanoma research: Meeting report from the “Melanoma Bridge”. Napoli, December 1st–4th 2015
title_full Future perspectives in melanoma research: Meeting report from the “Melanoma Bridge”. Napoli, December 1st–4th 2015
title_fullStr Future perspectives in melanoma research: Meeting report from the “Melanoma Bridge”. Napoli, December 1st–4th 2015
title_full_unstemmed Future perspectives in melanoma research: Meeting report from the “Melanoma Bridge”. Napoli, December 1st–4th 2015
title_short Future perspectives in melanoma research: Meeting report from the “Melanoma Bridge”. Napoli, December 1st–4th 2015
title_sort future perspectives in melanoma research: meeting report from the “melanoma bridge”. napoli, december 1st–4th 2015
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111349/
https://www.ncbi.nlm.nih.gov/pubmed/27846884
http://dx.doi.org/10.1186/s12967-016-1070-y
work_keys_str_mv AT asciertopaoloa futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT agarwalasanjiv futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT bottigerardo futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT cesanoalessandra futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT cilibertogennaro futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT daviesmichaela futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT demariasandra futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT dummerreinhard futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT eggermontalexanderm futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT ferronesoldano futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT fuyangxin futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT gajewskithomasf futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT garbeclaus futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT huberveronica futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT khleifsamir futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT krauthammermichael futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT lorogers futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT masuccigiuseppe futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT palmierigiuseppe futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT postowmichael futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT puzanovigor futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT silkann futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT sprangerstefani futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT stroncekdavidf futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT tarhiniahmad futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT taubejanism futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT testorialessandro futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT wangena futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT wargojennifera futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT yeecassian futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT zarourhassane futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT zitvogellaurence futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT foxbernarda futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT mozzillonicola futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT marincolafrancescom futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015
AT thurinmagdalena futureperspectivesinmelanomaresearchmeetingreportfromthemelanomabridgenapolidecember1st4th2015